Millions of Americans operate schedules that require them to start their day before dawn, a reality often taken as a necessary part of modern life. But for a significant portion of these early risers, the routine isn’t simply about a preference for quiet mornings. it’s a struggle against a powerful biological force. A modern clinical trial from researchers at Mass General Brigham suggests a potential solution for those experiencing debilitating fatigue linked to early morning shift work, offering a glimmer of hope for improved alertness, and safety. The study, published in NEJM Evidence, focuses on the drug solriamfetol (Sunosi) and its ability to combat the effects of shift work disorder.
Shift work disorder, characterized by disrupted sleep patterns and excessive daytime sleepiness, impacts an estimated 26% of workers who operate outside traditional 9-to-5 hours, according to the National Sleep Foundation. This includes those in essential roles like healthcare, transportation, and manufacturing, highlighting the broad societal implications of this often-overlooked condition. The challenge isn’t just about feeling tired; it’s about the real-world consequences of impaired cognitive function, increased accident risk, and diminished productivity.
The Biological Battle of Early Mornings
The core of the problem lies in our circadian rhythm – the internal biological clock that regulates sleep-wake cycles. “People who start work between 3 a.m. And 7 a.m. Are waking up at a time when the brain is biologically programmed to sleep,” explains Kirsi-Marja Zitting, PhD, an investigator with the Division of Sleep and Circadian Medicine in the Mass General Brigham Department of Medicine, and first author of the study. “That makes staying alert extraordinarily difficult, even when they are highly motivated.” This isn’t simply a matter of willpower; it’s a fundamental conflict between our natural physiology and the demands of the job. Workers face a “double burden,” Zitting adds, battling sleepiness during work hours and struggling to obtain sufficient rest when they finally have the opportunity.
Beyond Coffee: The Risks of Untreated Shift Work Disorder
The consequences of untreated shift work disorder extend far beyond personal discomfort. Reduced mental sharpness and lower productivity are common, but the risks escalate to include a significantly increased likelihood of car accidents and workplace injuries. While medications like modafinil are sometimes used to promote wakefulness, their effectiveness has primarily been studied in overnight shift workers, and they can potentially disrupt sleep later in the day, creating a vicious cycle. Research published in the journal Sleep Medicine Reviews details the complex interplay between shift work, circadian disruption, and health outcomes, including cardiovascular disease and metabolic disorders.
Solriamfetol Shows Promise in Clinical Trial
Solriamfetol, already approved by the Food and Drug Administration (FDA) for treating excessive daytime sleepiness associated with obstructive sleep apnea and narcolepsy, emerged as a promising candidate for addressing the challenges faced by early morning shift workers. The drug works by increasing levels of dopamine and norepinephrine in the brain, neurotransmitters that play a crucial role in promoting wakefulness and alertness. The recent clinical trial, involving 78 participants diagnosed with shift work disorder, randomly assigned individuals to receive either solriamfetol or a placebo over a four-week period.
Researchers assessed participants’ ability to stay awake in a controlled, low-stimulation environment that mirrored their typical work schedule. The results were clear: those who received solriamfetol demonstrated significantly improved alertness and were able to remain awake for longer periods during simulated work hours. Importantly, both participants and clinicians reported better overall functioning, improved work performance, and an enhanced ability to manage daily tasks. “The improvement we saw is clinically meaningful,” says senior author Charles A. Czeisler, PhD, MD, chief and senior physician of the Division of Sleep and Circadian Medicine in the Mass General Brigham Department of Medicine. “These workers were able to stay awake and alert throughout a full eight-hour shift, which has real implications for performance, safety, and quality of life.”
Looking Ahead: Further Research and Broader Applications
While the findings are encouraging, researchers emphasize the need for continued investigation. The current trial focused on otherwise healthy adults and lasted only four weeks. Long-term effects and the drug’s efficacy in diverse populations require further study. The team is currently enrolling participants in a follow-up clinical trial to evaluate solriamfetol’s impact on overnight shift workers, which could pave the way for broader FDA approval for treating shift work disorder across all types of non-traditional schedules. Details about the ongoing clinical trial (NCT04788953) are available on ClinicalTrials.gov.
This research underscores the importance of recognizing shift work disorder as a legitimate medical condition and seeking appropriate interventions. For those struggling with the challenges of early morning or irregular work schedules, consulting with a healthcare professional is a crucial first step. Addressing this often-invisible burden can not only improve individual well-being but also enhance safety and productivity across a wide range of industries.
Disclaimer: This article provides information for general knowledge and informational purposes only, and does not constitute medical advice. This proves essential to consult with a qualified healthcare professional for any health concerns or before making any decisions related to your health or treatment.
What are your experiences with shift work? Share your thoughts in the comments below, and please share this article with anyone who might find it helpful.
